Analgesic nephropathy prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
It has been suggested that in clinical practice, non-[[opioid]] analgesics, when possible, should be avoided for | It has been suggested that in clinical practice, non-[[opioid]] analgesics, when possible, should be avoided for long-term use due to their [[nephrotoxicity]]. | ||
==Prevention== | ==Prevention== | ||
It has been suggested that in clinical practice, non-[[opioid]] analgesics, when possible, should be avoided for | It has been suggested that in clinical practice, non-[[opioid]] analgesics, when possible, should be avoided for long-term use due to their [[nephrotoxicity]].<ref name="pmid28582877">{{cite journal| author=Yaxley J| title=Common analgesic agents and their role in analgesic nephropathy: A commentary of the evidence. | journal=Int J Risk Saf Med | year= 2016 | volume= 28 | issue= 4 | pages= 189-196 | pmid=28582877 | doi=10.3233/JRS-170735 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28582877 }} </ref> | ||
==References== | ==References== | ||
Latest revision as of 16:08, 6 July 2020
|
Analgesic nephropathy Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Analgesic nephropathy prevention On the Web |
|
American Roentgen Ray Society Images of Analgesic nephropathy prevention |
|
Risk calculators and risk factors for Analgesic nephropathy prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shakiba Hassanzadeh, MD[2]
Overview
It has been suggested that in clinical practice, non-opioid analgesics, when possible, should be avoided for long-term use due to their nephrotoxicity.
Prevention
It has been suggested that in clinical practice, non-opioid analgesics, when possible, should be avoided for long-term use due to their nephrotoxicity.[1]
References
- ↑ Yaxley J (2016). "Common analgesic agents and their role in analgesic nephropathy: A commentary of the evidence". Int J Risk Saf Med. 28 (4): 189–196. doi:10.3233/JRS-170735. PMID 28582877.